Optofluidics, Inc. is a venture backed life-sciences company that is developing microfluidic and biophotonic nanomanipulation technologies for biological, material science, and pharmaceutical applications. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin NanoTechnology Institute. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.
Our research focuses on developing strategic and surface nano-optical methods for controlling the architecture of molecules and materials on a 1-100 nm scale. Our researchers, with backgrounds ranging from medicine, biology, chemistry, physics and material science, are working together in solving fundamental and applied problems of modern nanoscience.
Mersana Therapeutics employs its biodegradable polymer platform (Fleximer®) to create new and better medicines. We are advancing our own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. We also leverage the versatility of Fleximer through partnerships to overcome the safety, efficacy, and delivery challenges of nucleic acids, biologics, and small molecules in numerous therapeutic areas.